Dear Colleague,
GTC’s Cancer Summit - Novel Approaches to Drug Discovery is taking place on
November 8-9 in Boston, MA and will feature two parallel conferences: 1)
2nd
Cancer Epigenetics 2)
Protein Kinases and Drug Design. Join and meet
with leading experts from the industry and academia to discuss the latest
cutting edge approaches and discoveries in cancer. The epigenetics conference
will update you on the latest novel mechanisms, therapeutics, drug discovery,
developments, biomarkers and diagnostics for cancer epigenetics. The protein
kinases conference will update you on the most recent advances in drug design
and development, selective and non-selective kinases inhibitors, hit and target
identification, oncology kinases and inhibitors, and other kinases targets.
Experts will also share their positive and negative experiences on how
predictive preclinical models are with clinical efficacy and toxicology.
Sessions of the 2nd Cancer Epigenetics conference:
Epigenetic Mechanisms in Cancer
Drug Discovery in Cancer Epigenetics
Epigenetic Biomarkers and Diagnostics
Preclinical and Clinical Development
Recent Advances in Cancer Epigenetics
Sessions of the Protein Kinases and Drug Design conference:
Recent Advances in Drug Design & Development
Selective vs Non-selective Kinases Inhibitors
Recent Advancements in Hit and Target Identification
Novel Oncology Kinases & Inhibitors
Preclinical Models – How Predictive are They?
Kinase Targets in Pre-clinical and Clinical Trials
To view the agenda,
click
here.
To view the speaker list,
click here.
Sign up for the summit
pass to have access to both tracks of the summit. Or bring a team of 3 for the
price of 2 by
Registering
with the coupon code rcdvb!We look forward to seeing you at the
conference!
Sincerely,
2012 Cancer Summit - Novel Approaches to Drug Discovery Summit Organizing Committee
|
What Past Delegates said:
“Fantastic opportunity to see the very latest research in epigenetics
drug-discovery.” - Rab Prinjha, VP Head of Epinova DPU, GSK
"The conference was a huge success, bringing together the top-leaders and
innovators in the protein kinase field, where new screening technologies and the
most late-breaking clinical kinase targeting drugs were disclosed. The group is
growing in numbers each year, but still remains quite manageable to allow for
one-on-one interactions and networking. This conference has become indispensable
for those in the kinase drug discovery field." - Mark Mulvihill, Associate
Director of Chemistry, Oncology, OSI Pharmaceuticals
"The meeting provides an excellent snapshot of the up-to-date state of kinase
drug discovery with inputs from both academia and industry. It covers all
aspects of the field starting from discussion of well established as well as new
emerging kinase targets to the novel classes of small molecule inhibitors to new
exciting technologies to study kinases. It also provides ample opportunities for
networking and establishing new collaborations." - Dr. Alexei Degterev,
Assistant Professor, Tufts University
“An excellent meeting with good organization and top quality speakers and
attendees from academia and bio-pharmaceutical as well and biotechnology
industry.” - Pfizer |
|
